Eikon Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
The Column Group and its affiliates, including managing partners Tim Kutzkey and Peter Svennilson, reported an aggregate beneficial ownership of 11.6% in Eikon Therapeutics, Inc. following recent IPO purchases and preferred stock conversions.